FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation’s Investigational Drug to Treat Diabetes

The U.S. Food and Drug Administration voted to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval to improve glycemic control in adults with type 1 diabetes and in adults with type 2 diabetes (MannKind Corporation)